Latest Financial Results
Q1 2021
Quarter Ended Mar 31, 2021
Email Alerts
Sign upStock Information
Company Overview
Cellectar Biosciences is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing proprietary drugs independently and through research and development collaborations. The company’s core objective is to leverage its proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform to develop PDCs that specifically target cancer cells, delivering improved efficacy and better safety as a result of fewer off-target effects. The company’s PDC platform possesses the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations.
The company’s product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope) directly to cancer cells, while limiting exposure to healthy cells unlike many traditional on-market treatment options. CLR 131, is currently in a clinical study for hematologic malignancies and a pediatric safety study, one preclinical PDC chemotherapeutic program (CLR 1900) and multiple partnered PDC assets.
For more information, please visit www.cellectar.com or join the conversation by liking and following us on the company’s social media channels: Twitter, LinkedIn, and Facebook.
Investor Contact Information
Company
Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932
T: 608-441-8120
F: 608-441-8121
investors@cellectar.com
Investor Relations
LifeSci Advisors
Monique Kosse
Managing Director
T: 212-915-3820
monique@lifesciadvisors.com
Transfer Agent
American Stock Transfer
Tamara Cajuste
Relationship Manager
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8300 ext. 6462
M: 347-939-9659
F: 718-765-8712
tcajuste@astfinancial.com
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.